French cultivated meals firm Gourmey claims it has change into the primary within the class to obtain an impartial validation confirming that its manufacturing mannequin is scalable and economically viable.
A techno-economic evaluation from Arthur D. Little concluded that Gourmey’s 5,000-liter bioreactor system can obtain the manufacturing of cultivated meat at $3.43 per pound (€7 per kilogram), which means that the corporate is on the trail to cost parity with out the necessity for speculative applied sciences or mega-scale infrastructure.
Gourmey’s platform is constructed round a second-generation expertise stack designed for cost-effective deployment. It combines steady manufacturing,
undifferentiated cell biomass, and suspension-based cell cultures.
Legacy biopharma strategies have been changed with food-grade, cost-effective processes purpose-built for scale. Gourmey’s asset-light mannequin avoids reliance on advanced inputs or customized infrastructure, which means it has minimal capital necessities in comparison with conventional programs.
“From potential to proof”
Arthur D. Little’s evaluation finds that Gourmey’s mannequin, with achievable and clearly outlined course of optimizations, delivers:
- €7/kg ($3.4/lb) manufacturing value at present 5,000L scale.
- CapEx beneath €35 million per facility, modular and repeatable, with output of 1,700 tons (3 million+ kilos) utilizing simply six 5,000L bioreactors.
- Steady runs with excessive cell density.
- Cell feed at €0.20/L, with no development components or fetal bovine serum.
- Full suspension tradition, eliminating the necessity for scaffolds or microcarriers.
- No reliance on pharmaceutical inputs.
“Gourmey’s platform was assessed to achieve under €10/kg for completed product, the bottom value stage in publicly reported techno-economic fashions thus far, [while] demonstrating best-in-class CapEx effectivity,” mentioned Clément Santander, Associate at Arthur D. Little. “This marks a shift from potential to proof.”
“Globally scalable”
Gourmey’s first providing is a cultivated different to the French delicacy foie gras. The product has acquired reward from Michelin-starred cooks, and is backed by a culinary advisory board spanning Tokyo, San Francisco, and Copenhagen. Demand is already reported to be exceeding deliberate manufacturing capability.
Gourmey has raised over €65 million — together with a €48 million round in 2022 — and has seven regulatory filings underway in areas reminiscent of the EU, the UK, Switzerland, Singapore, and the US. The corporate says it has a transparent path to profitability, and is exploring go-to-market methods for each high-value
choices and future commodity proteins. This contains ongoing discussions with main international protein companies.
With a proprietary embryonic stem cell platform and a portfolio of greater than 50 patent filings throughout the cultivated meat worth chain, Gourmey’s expertise is alleged to allow species-agnostic scale, low-cost inputs, and steady manufacturing with out downstream complexity.
“Our focus has at all times been on constructing one thing technically sound, economically viable, and globally scalable to maximise our influence,” mentioned Nicolas Morin-Forest, co-founder and CEO of Gourmey. “The cultivated meat business has reached a degree the place proof issues greater than guarantees. This impartial validation helps transfer the dialog ahead to operational
actuality. It exhibits that, with the proper technological decisions supporting a sensible scale-up roadmap, cultivated proteins will change into a significant answer to enrich present manufacturing programs.”
